J&J hopes to boost vax business with Crucell buy

The world's largest diversified healthcare group Johnson & Johnson said Wednesday it will buy Dutch biotechnology firm Crucell for €1.75 billion ($2.4 billion)--a move that will help it boost its vaccine business. J&J said Crucell's board has agreed to the takeover offer and has recommended the bid to its shareholders. Article

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.